NCT02542267已完成不适用
Post-Approval Study of the GORE® VIABAHN® Endoprosthesis for the Treatment of In-Stent Restenosis (ISR) in the Superficial Femoral Artery (SFA)
W.L.Gore & Associates41 个研究点 分布在 4 个国家目标入组 108 人开始时间: 2015年9月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 108
- 试验地点
- 41
- 主要终点
- Number of Subjects Free From Procedure and Device-Related Serious Adverse Events Within 30 Days of Index Procedure
研究概览
简要总结
The objective of the ISR 14-04 study is to evaluate post-market safety and effectiveness of GORE® VIABAHN® Endoprosthesis for treatment of In-Stent Restenosis of the Superficial Femoral Artery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient has a previously implanted (> 30 days) non-covered stent(s) located in the SFA
- •Patient has life-style limiting claudication, resting leg pain or minor tissue loss (Rutherford Category 2 - 5)
- •Patient demonstrates an Ankle Brachial Index (ABI) <=0.
- •If ABI >0.9 or not measurable, patient is eligible for study if Toe Brachial Index is <=0.5
- •Patient has >=50% in-stent restenosis and / or an occlusion in a previously implanted (>30 days) non-covered stent(s) located in the superficial femoral artery defined as beginning at least 1cm below the origin of the profunda femoris artery and ending at least 1cm above the intercondylar notch.
- •Patient has a maximum total lesion length of 270mm, consisting of in-stent and adjacent occlusive disease
- •Patient has a reference vessel diameter between 4.0 and 6.5mm
- •Patient has at least one patent infrapopliteal runoff vessel (<50% stenosis) not requiring reintervention
- •Note: Additional Inclusion Criteria may apply
排除标准
- •Patient has a known allergy to stent graft components (nickel-titanium or expanded-polytetrafluoroethylene)
- •Patient has a known intolerance to anticoagulation or antiplatelet therapy
- •Patient has known coagulation disorder, including hypercoagulability.
- •Patient has major distal amputation (above the transmetatarsal)
- •Patient has any previous surgery in the target vessel
- •Patient has had previous target vessel in-stent restenosis treated by relining with another stent
- •Patient has untreated flow-limiting aortoiliac stenotic disease
- •Note: Additional Exclusion Criteria may apply
结局指标
主要结局
Number of Subjects Free From Procedure and Device-Related Serious Adverse Events Within 30 Days of Index Procedure
时间窗: 30 Days
Primary Safety is defined as freedom from procedure and device-related serious adverse events within 30 days of index procedure
Primary Effectiveness
时间窗: 12 Months
Primary Effectiveness is Primary Patency defined as patent blood flow through the study device, which requires either a Peak Systolic Velocity Ratio measurement ≤ 2.5 or patent flow indicated by the Core Lab, and without repeat intervention measured at 12 months and assessed by Kaplan-Meier analysis.
次要结局
- Change in Ankle Brachial Index at 30 Days(Pre-procedure and 30 Days)
- Primary Patency at 30 Days and 12, 24, and 36 Months(30 days and 12, 24, and 36 months)
- Change in Rutherford Category at 30 Days(Pre-procedure and 30 Days)
- Number of Subjects With Acute Procedural Success(During hospitalization, approximately 1-2 days)
- Change in Rutherford Category at 2 Years(Pre-procedure and 2 Years)
- Change in Rutherford Category at 3 Years(Pre-procedure and 3 Years)
- Primary Assisted Patency at 30 Days and 12, 24, and 36 Months(30 days and 12, 24, and 36 months)
- Freedom From Target Lesion Revascularization at 30 Days and 12, 24, and 36 Months(30 days and 12, 24, and 36 months)
- Change in Ankle Brachial Index at 1 Year(Pre-procedure and 1 Year)
- Secondary Patency at 30 Days and 12, 24, and 36 Months(30 days and 12, 24, and 36 months)
- Freedom From Major Amputation at 30 Days and 12, 24, and 36 Months(30 days and 12, 24, and 36 months)
- Change in Ankle Brachial Index at 2 Years(Pre-procedure and 2 Years)
- Change in Ankle Brachial Index at 3 Years(Pre-procedure and 3 Years)
- Change in Rutherford Category at 1 Year(Pre-procedure and 1 Year)
- Stent Fracture at 12, 24, and 36 Months(12, 24, and 36 months)
研究者
研究点 (41)
Loading locations...
相似试验
已完成
不适用
GORE® VIABAHN® Endoprosthesis Post-Marketing Surveillance StudyVascular Stent-Graft StenosisNCT04429243W.L.Gore & Associates124
已完成
不适用
Evaluation of the GORE® VIABAHN® Endoprosthesis for the Treatment of Popliteal Artery Aneurysm (PAA)Popliteal Artery AneurysmNCT02462876W.L.Gore & Associates60
已完成
不适用
GORE® VIABAHN® Endoprosthesis Post-Marketing Surveillance Study (JPS 16-03)Peripheral Arterial DiseaseNCT04706273W.L.Gore & Associates321
已完成
不适用
GORE VIABAHN Endoprosthesis With Heparin Bioactive Surface in the Treatment of SFA Obstructive Disease (VIPER)Peripheral Vascular DiseasesNCT00541307W.L.Gore & Associates119
进行中（未招募）
不适用
VIATORR Device RegistryChronic Liver DiseaseNCT05661331W.L.Gore & Associates196